B-cell Chronic Lymphocytic Leukemia (CLL)
Chronic Lymphocytic Leukemia is a slow-growing B-cell malignancy marked by lymphocytosis and immune dysfunction. Genetic abnormalities strongly influence disease behavior.
Biomarkers used in this indication
Each approval combines this indication with specific biomarker criteria and a therapy. Select a therapy from the tables below to open its FDA-defined testing pathway.
Defined explicitly for B-cell Chronic Lymphocytic Leukemia (CLL) in FDA labeling.
| Biomarker | Biomarker criteria | Therapies |
|---|---|---|
| TP53 |
|
Defined at the solid tumor level and applicable to B-cell Chronic Lymphocytic Leukemia (CLL) and other solid tumor cancers.
No tumor-agnostic biomarker approvals are currently mapped for this indication.
Therapies with biomarker-defined approvals
Each therapy below has at least one FDA companion diagnostic approval tied to B-cell Chronic Lymphocytic Leukemia (CLL). Select a therapy to view the specific approval and eligible tests.
TP53 (Deletion chromosome 17p (17p-))